8-KRegulation FDExhibits & Filings

QUEST DIAGNOSTICS INC 8-K Report, Regulation FD Disclosure (Mar 19, 2025)

Filed March 19, 2025For Securities:DGX

Summary

Quest Diagnostics Incorporated (DGX) filed an 8-K on March 19, 2025, to announce its Investor Day event. During this event, the company's leadership team is set to discuss strategies aimed at fostering sustainable growth and enhancing long-term shareholder value. A key component of this announcement is the issuance of a press release that reiterates previously provided guidance for the full-year 2025 and outlines the company's outlook beyond 2025. Investors should note that the press release and presentation materials, furnished as exhibits, contain forward-looking statements. While these provide insight into management's current expectations and long-term vision, they are subject to risks and uncertainties that could materially impact actual results. The company has referenced its SEC filings, including its most recent 10-K, for a comprehensive discussion of these potential risks.

Key Highlights

  • 1Quest Diagnostics is hosting an Investor Day on March 19, 2025.
  • 2Leadership will present strategies for sustainable growth and long-term shareholder value.
  • 3A press release was issued reiterating full-year 2025 guidance.
  • 4The company provided its long-term outlook beyond 2025.
  • 5Investor Day materials will be available on the company's investor relations website.
  • 6The filing includes a press release as Exhibit 99.1.
  • 7Forward-looking statements are included in the disseminated materials, subject to inherent risks.

Frequently Asked Questions

The primary purpose of this 8-K filing is to inform investors about Quest Diagnostics' Investor Day event scheduled for March 19, 2025, where leadership will discuss business strategies and long-term outlook. It also includes a press release reiterating 2025 guidance and providing an outlook beyond 2025.

The press release furnishing information discussed at Investor Day is included as Exhibit 99.1 to this 8-K. Additionally, presentation materials used by the leadership team have been posted on the 'Events and Presentations' page of Quest Diagnostics' investor relations website.

This filing does not introduce new financial guidance for 2025. Instead, the accompanying press release reiterates previously issued guidance for the full-year 2025.

The forward-looking statements within the press release and presentation materials are subject to various risks and uncertainties. These include potential adverse results from government investigations or legal actions, competitive pressures, complexities in billing and reimbursement, regulatory changes, shifts in customer and payer relationships, and other factors detailed in Quest Diagnostics' most recent SEC filings (10-K, 10-Q, and other 8-Ks).